This analysis examines the historical and forecast performance for Amgen in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
Benchmark Amgen’s performance against key rivals in the ethical pharmaceutical sector
Assess how Amgen’s commercial performance out to 2013 will be impacted by recent safety concerns relating to the ESA product class
Analyze Amgen’s diversification strategy which will be heavily reliant on the launch of denosumab indicated for osteoporosis and bone metastases
